Leveraging the Medicines for Malaria Venture malaria and pathogen boxes to discover chemical inhibitors of East Coast fever

Chemotherapy of East Coast fever, a lymphoproliferative cancer-like disease of cattle causing significant economic losses in Africa, is largely dependent on the use of buparvaquone, a drug that was developed in the late 1980's. The disease is caused by the tick-borne protozoan pathogen Theileri...

Full description

Bibliographic Details
Main Authors: James Nyagwange, Elias Awino, Edwin Tijhaar, Nicholas Svitek, Roger Pelle, Vishvanath Nene
Format: Article
Language:English
Published: Elsevier 2019-04-01
Series:International Journal for Parasitology: Drugs and Drug Resistance
Online Access:http://www.sciencedirect.com/science/article/pii/S221132071830174X
id doaj-a4ac78b50dec44dc8fabf424bf1dba2a
record_format Article
spelling doaj-a4ac78b50dec44dc8fabf424bf1dba2a2020-11-25T02:15:40ZengElsevierInternational Journal for Parasitology: Drugs and Drug Resistance2211-32072019-04-0198086Leveraging the Medicines for Malaria Venture malaria and pathogen boxes to discover chemical inhibitors of East Coast feverJames Nyagwange0Elias Awino1Edwin Tijhaar2Nicholas Svitek3Roger Pelle4Vishvanath Nene5International Livestock Research Institute, P. O. Box 30709, Nairobi, Kenya; Cell Biology and Immunology Group, Wageningen University, the NetherlandsInternational Livestock Research Institute, P. O. Box 30709, Nairobi, KenyaCell Biology and Immunology Group, Wageningen University, the NetherlandsInternational Livestock Research Institute, P. O. Box 30709, Nairobi, KenyaBiosciences Eastern and Central Africa, International Livestock Research Institute (BecA-ILRI) Hub, P. O. Box 30709, Nairobi, KenyaInternational Livestock Research Institute, P. O. Box 30709, Nairobi, Kenya; Corresponding author.Chemotherapy of East Coast fever, a lymphoproliferative cancer-like disease of cattle causing significant economic losses in Africa, is largely dependent on the use of buparvaquone, a drug that was developed in the late 1980's. The disease is caused by the tick-borne protozoan pathogen Theileria parva. Buparvaquone can be used prophylactically and it is also active against tropical theileriosis, caused by the related parasite Theileria annulata. Recently, drug resistance was reported in T. annulata, and could occur in T. parva. Using a 3H-thymidine incorporation assay we screened 796 open source compounds from the Medicines for Malaria Venture (MMV) to discover novel chemicals with potential inhibitory activity to T. parva. We identified nine malaria box compounds and eight pathogen box compounds that inhibited the proliferation of F100TpM, a T. parva infected lymphocyte cell line. However, only two compounds, MMV008212 and MMV688372 represent promising leads with IC50 values of 0.78 and 0.61 μM, respectively, and CC50 values > 5 μM. The remaining compounds exhibited a high degree of toxicity (CC50 values < 1.09 μM) on the proliferation of bovine peripheral blood mononuclear cells stimulated with concanavalin A. We also tested the anti-cancer drug, dasatinib, used in the chemotherapy of some leukemias. Dasatinib was as active and safe as buparvaquone in vitro, with an IC50 of 5 and 4.2 nM, respectively, and CC50 > 10 μM. Our preliminary data suggest that it may be possible to repurpose compounds from the cancer field as well as MMV as novel anti-T. parva molecules. Keywords: Medicines for malaria venture, Malaria box, East coast fever, Dasatinib, Theileria parvahttp://www.sciencedirect.com/science/article/pii/S221132071830174X
collection DOAJ
language English
format Article
sources DOAJ
author James Nyagwange
Elias Awino
Edwin Tijhaar
Nicholas Svitek
Roger Pelle
Vishvanath Nene
spellingShingle James Nyagwange
Elias Awino
Edwin Tijhaar
Nicholas Svitek
Roger Pelle
Vishvanath Nene
Leveraging the Medicines for Malaria Venture malaria and pathogen boxes to discover chemical inhibitors of East Coast fever
International Journal for Parasitology: Drugs and Drug Resistance
author_facet James Nyagwange
Elias Awino
Edwin Tijhaar
Nicholas Svitek
Roger Pelle
Vishvanath Nene
author_sort James Nyagwange
title Leveraging the Medicines for Malaria Venture malaria and pathogen boxes to discover chemical inhibitors of East Coast fever
title_short Leveraging the Medicines for Malaria Venture malaria and pathogen boxes to discover chemical inhibitors of East Coast fever
title_full Leveraging the Medicines for Malaria Venture malaria and pathogen boxes to discover chemical inhibitors of East Coast fever
title_fullStr Leveraging the Medicines for Malaria Venture malaria and pathogen boxes to discover chemical inhibitors of East Coast fever
title_full_unstemmed Leveraging the Medicines for Malaria Venture malaria and pathogen boxes to discover chemical inhibitors of East Coast fever
title_sort leveraging the medicines for malaria venture malaria and pathogen boxes to discover chemical inhibitors of east coast fever
publisher Elsevier
series International Journal for Parasitology: Drugs and Drug Resistance
issn 2211-3207
publishDate 2019-04-01
description Chemotherapy of East Coast fever, a lymphoproliferative cancer-like disease of cattle causing significant economic losses in Africa, is largely dependent on the use of buparvaquone, a drug that was developed in the late 1980's. The disease is caused by the tick-borne protozoan pathogen Theileria parva. Buparvaquone can be used prophylactically and it is also active against tropical theileriosis, caused by the related parasite Theileria annulata. Recently, drug resistance was reported in T. annulata, and could occur in T. parva. Using a 3H-thymidine incorporation assay we screened 796 open source compounds from the Medicines for Malaria Venture (MMV) to discover novel chemicals with potential inhibitory activity to T. parva. We identified nine malaria box compounds and eight pathogen box compounds that inhibited the proliferation of F100TpM, a T. parva infected lymphocyte cell line. However, only two compounds, MMV008212 and MMV688372 represent promising leads with IC50 values of 0.78 and 0.61 μM, respectively, and CC50 values > 5 μM. The remaining compounds exhibited a high degree of toxicity (CC50 values < 1.09 μM) on the proliferation of bovine peripheral blood mononuclear cells stimulated with concanavalin A. We also tested the anti-cancer drug, dasatinib, used in the chemotherapy of some leukemias. Dasatinib was as active and safe as buparvaquone in vitro, with an IC50 of 5 and 4.2 nM, respectively, and CC50 > 10 μM. Our preliminary data suggest that it may be possible to repurpose compounds from the cancer field as well as MMV as novel anti-T. parva molecules. Keywords: Medicines for malaria venture, Malaria box, East coast fever, Dasatinib, Theileria parva
url http://www.sciencedirect.com/science/article/pii/S221132071830174X
work_keys_str_mv AT jamesnyagwange leveragingthemedicinesformalariaventuremalariaandpathogenboxestodiscoverchemicalinhibitorsofeastcoastfever
AT eliasawino leveragingthemedicinesformalariaventuremalariaandpathogenboxestodiscoverchemicalinhibitorsofeastcoastfever
AT edwintijhaar leveragingthemedicinesformalariaventuremalariaandpathogenboxestodiscoverchemicalinhibitorsofeastcoastfever
AT nicholassvitek leveragingthemedicinesformalariaventuremalariaandpathogenboxestodiscoverchemicalinhibitorsofeastcoastfever
AT rogerpelle leveragingthemedicinesformalariaventuremalariaandpathogenboxestodiscoverchemicalinhibitorsofeastcoastfever
AT vishvanathnene leveragingthemedicinesformalariaventuremalariaandpathogenboxestodiscoverchemicalinhibitorsofeastcoastfever
_version_ 1724894788532043776